Shares of Ascendis Pharma A/S (NASDAQ:ASND) have received a consensus recommendation of “Hold” from the eleven ratings firms that are presently covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $36.45.
A number of research firms have recently weighed in on ASND. HC Wainwright reaffirmed a “buy” rating on shares of Ascendis Pharma A/S in a research report on Wednesday, December 13th. Bank of America lowered their price objective on Ascendis Pharma A/S from $46.00 to $43.00 and set a “buy” rating on the stock in a research report on Friday, November 17th. Wells Fargo & Company reissued a “buy” rating and issued a $51.00 price target on shares of Ascendis Pharma A/S in a report on Friday, September 22nd. Credit Suisse Group reissued an “outperform” rating and issued a $50.00 price target (up from $30.00) on shares of Ascendis Pharma A/S in a report on Friday, September 22nd. Finally, Wedbush reissued an “outperform” rating and issued a $10.71 price target (down from $65.00) on shares of Ascendis Pharma A/S in a report on Friday, September 22nd.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Bank of Montreal Can increased its position in shares of Ascendis Pharma A/S by 127.4% during the 2nd quarter. Bank of Montreal Can now owns 4,535 shares of the biotechnology company’s stock valued at $126,000 after purchasing an additional 2,541 shares during the last quarter. Bank of America Corp DE boosted its holdings in Ascendis Pharma A/S by 23.6% during the 1st quarter. Bank of America Corp DE now owns 5,345 shares of the biotechnology company’s stock valued at $150,000 after acquiring an additional 1,020 shares during the period. Victory Capital Management Inc. purchased a new position in Ascendis Pharma A/S during the 3rd quarter valued at $194,000. Deschutes Portfolio Strategy LLC purchased a new position in Ascendis Pharma A/S during the 2nd quarter valued at $238,000. Finally, Aperio Group LLC purchased a new position in Ascendis Pharma A/S during the 3rd quarter valued at $241,000. 78.93% of the stock is currently owned by institutional investors.
Ascendis Pharma A/S (ASND) traded up $0.16 during mid-day trading on Friday, hitting $39.28. The stock had a trading volume of 48,000 shares, compared to its average volume of 116,015. Ascendis Pharma A/S has a 12-month low of $19.21 and a 12-month high of $42.00.
TRADEMARK VIOLATION WARNING: “Ascendis Pharma A/S (ASND) Receives Average Rating of “Hold” from Brokerages” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another domain, it was copied illegally and reposted in violation of international copyright & trademark laws. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/01/14/ascendis-pharma-as-asnd-receives-average-rating-of-hold-from-brokerages.html.
About Ascendis Pharma A/S
Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.